AstraZeneca Nexium Cleared For Lowering Risk Of NSAID-Related Ulcers
This article was originally published in The Tan Sheet
Executive Summary
A supplemental approval for Nexium will allow AstraZeneca to position the proton pump inhibitor as an alternative to switching patients to a COX-2 to reduce the risk of gastric ulcers associated with continuous NSAID therapy